In:
Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 27, No. 8 ( 2021-04-08), p. 1068-1079
Kurzfassung:
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a new antihyperglycemic
class with the demonstrated advantage of reducing major adverse cardiovascular events (MACE) among individuals with type 2 diabetes (T2DM), atherosclerotic cardiovascular disease, or high cardiovascular
risk. Objective: Τo summarize the evidence of systematic reviews (SRs) that assess MACE (cardiovascular mortality,
nonfatal myocardial infarction, and stroke) and hospitalizations for heart failure in GLP-1RAs-treated patients and to evaluate possible overlap in pertinent SRs. Methods: We performed a comprehensive search via MEDLINE, Cochrane Library, and PROSPERO databases
up to February 23, 2020, for SRs examining cardiovascular outcomes of GLP-1RAs in T2DM patients. Three independent authors extracted data and assessed the methodological quality of the included SRs using the
ROBIS tool. Results : We found 37 SRs – published between 2009 and 2020 in English – of which 35 collected data only
from randomized clinical trials while two from observational studies as well. The methodological quality of the 37 SRs ranged from low to high, while only 3 have evaluated the overall quality of evidence outcome using the
Grading of Recommendations Assessments, Development and Evaluation (GRADE) approach. All the included SRs showed cardiovascular safety of GLP-1RAs while the latest ones demonstrated a reduction in composite
MACE endpoint as well as its every individual component and heart failure hospitalizations. Conclusion: In the first overview of SRs about cardiovascular outcomes of GLP-1RAs, they proved favorable
effects on reducing cardiovascular events in T2DM patients. There are, however, many overlapping reviews based on relatively few cardiovascular outcomes trials.
Materialart:
Online-Ressource
ISSN:
1381-6128
DOI:
10.2174/1381612827666210119103153
Sprache:
Englisch
Verlag:
Bentham Science Publishers Ltd.
Publikationsdatum:
2021
SSG:
15,3
Permalink